Ligand Pharmaceuticals Incorporated (LGND)

Return on assets (ROA)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	52,154	16,481	27,158	23,973	-33,361	-21,293	-7,974	23,646	57,138	68,316	47,892	39,253	-2,985	-16,111	-24,661	-61,166	629,302	594,185	676,798	764,377
Total assets	US$ in thousands	787,216	769,226	758,105	811,076	762,668	1,050,600	1,076,290	1,105,180	1,297,590	1,273,660	1,256,280	1,295,120	1,362,280	1,247,450	1,242,940	1,185,920	1,494,920	1,547,480	1,801,840	1,913,990
ROA		6.63%	2.14%	3.58%	2.96%	-4.37%	-2.03%	-0.74%	2.14%	4.40%	5.36%	3.81%	3.03%	-0.22%	-1.29%	-1.98%	-5.16%	42.10%	38.40%	37.56%	39.94%

December 31, 2023 calculation

ROA = Net income (ttm) ÷ Total assets
= $52,154K ÷ $787,216K
= 6.63%

Ligand Pharmaceuticals, Inc.'s return on assets (ROA) has shown positive trends over the past eight quarters, with Q4 2023 reporting the highest ROA at 6.63%. This indicates that the company generated a profit of 6.63 cents for every dollar of assets it holds. The fluctuation in ROA from negative figures in Q4 2022 to positive figures in Q1 2023 suggests a possible turnaround in the company's asset utilization and profitability. In general, Ligand Pharmaceuticals, Inc. appears to be efficiently utilizing its assets to generate profits, with an overall improvement in ROA performance over the given period.